Open Access
Abnormal DNA methylation, epigenetics, and prostate cancer
William G Nelson1,Srinivasan Yegnasubramanian1,Agoston T Agoston1,Patrick J Bastian1,Byron H Lee1,Masashi Nakayama1,Angelo M De Marzo1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Brady Urological Institute, Baltimore, MD 21231, USA.
DOI: 10.2741/2385 Volume 12 Issue 11, pp.4254-4266
Published: 01 May 2007
(This article belongs to the Special Issue Genes in genitourinary neoplasia)

Human prostatic carcinogenesis is characterized by the accumulation of both genetic and epigenetic alterations. The epigenetic changes appear earlier and more consistently, and because the DNA sequence remains intact, may be therapeutically reversible. The mechanism(s) by which epigenetic changes appear during the pathogenesis of prostate cancer have not been established. Nonetheless, new methods for the detection of abnormal DNA methylation, a molecular biomarker of epigenetic alterations, are poised to provide clinical tests potentially useful for prostate cancer detection and diagnosis. In addition, new drugs targeting DNA methyltransferases and other enzymes involved in the maintenance of chromatic structure have been introduced into clinical trials for the treatment of advanced prostate cancers. If sufficiently safe strategies for chromatin modulation can be discovered and developed, epigenetic alterations may become rational targets for both prostate cancer prevention and prostate cancer treatment.

Share and Cite
William G Nelson, Srinivasan Yegnasubramanian, Agoston T Agoston, Patrick J Bastian, Byron H Lee, Masashi Nakayama, Angelo M De Marzo. Abnormal DNA methylation, epigenetics, and prostate cancer. Frontiers in Bioscience-Landmark. 2007. 12(11); 4254-4266.